Latest news with #contractManufacturing
Yahoo
19-06-2025
- Business
- Yahoo
Why AI Stock Jabil Crushed the Market on Tuesday
The contract electronics manufacturer delivered solid third-quarter results. Its business is benefiting handsomely from the proliferation of artificial intelligence (AI), and it's also doing well supplying cloud computing customers. 10 stocks we like better than Jabil › The intense take-up of artificial intelligence (AI) has been a powerful motor driving contract electronics manufacturer Jabil (NYSE: JBL) lately. It also helped power the company's latest quarterly results, which were published Tuesday morning. Investors very much liked what they saw in the numbers, and rewarded the company by boosting its share price nearly 9% higher on the day. Jabil's fiscal third quarter of 2025 results were posted before market open, and they set the tone for the stock that day. Revenue rose by a sturdy 16% year over year to just over $7.8 billion, handily beating the average analyst estimate of $7 billion. The story was similar on the bottom line, with "core" -- i.e. non-GAAP (generally accepted accounting principles) adjusted -- net income rising 21% to $279 million, or $2.55 per share. The latter number was well above the consensus $2.29 projected by analysts tracking Jabil stock. Management attributed the double-digit gains to growth in expanding end markets, such as data centers infrastructure, and cloud computing. Its intelligent infrastructure segment did particularly well, thanks greatly to intensifying demand for artificial intelligence (AI) solutions. Meanwhile, Jabil announced it is to invest roughly $500 million to expand its manufacturing footprint in the Southwest U.S., specifically targeting the AI and cloud businesses. The company wrote that this will "enable new large-scale manufacturing capabilities, capital investments, and workforce development." Such facilities should come onstream in mid-2026, it added. Jabil also proffered guidance for both its current quarter and the entirety of fiscal 2025. For the latter period, it's anticipating revenue of $29 billion, filtering down into adjusted net income of $9.33 per share. Those figures in fiscal 2024 were a respective $28.9 billion, and $8.49. Even with that post-earnings pop, Jabil remains a somewhat under-the-radar play on the explosion of AI. As such, I'd flag it as a sleeper stock in that pack, and one well worth consideration as a buy. Before you buy stock in Jabil, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Jabil wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why AI Stock Jabil Crushed the Market on Tuesday was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
CNA
22-05-2025
- Business
- CNA
Samsung BioLogics spin-off to separate contract drug making, new growth drivers
SEOUL :South Korean drug maker Samsung BioLogics said on Thursday it plans to separate the company into contract manufacturing and development companies, to help allay customer concerns about conflicts of interest between businesses. BioLogics said in a regulatory filing that it will keep its drug contract manufacturing business while spinning off a business overseeing subsidiaries, including biosimilar drug developer Samsung Bioepis, as well as new investments. The new spun-off company will tentatively be called Samsung Episholdings, the filing said. "With the spin off, we expect to have more opportunities to explore next-generation growth drivers," Samsung Bioepis said in a statement. BioLogics counts tech giant Samsung Electronics and builder Samsung C&T as its major shareholders. Kim Soo-hyun, head of research at DS Investment & Securities, said the deal may pave the way for Samsung C&T to sell some of its stake in the separated company and buy shares in Samsung Electronics, increasing the group's grip on the conglomerate's crown jewel. Shares in BioLogics, which had risen 7.1 per cent a day earlier after local media reports about a potential spin-off, rose as much as 8.2 per cent on Thursday before paring gains.
